Literature DB >> 28736230

Pro-Inflammatory Chemokines and Cytokines Dominate the Blister Fluid Molecular Signature in Patients with Epidermolysis Bullosa and Affect Leukocyte and Stem Cell Migration.

Vitali Alexeev1, Julio Cesar Salas-Alanis2, Francis Palisson3, Lila Mukhtarzada1, Giulio Fortuna4, Jouni Uitto1, Andrew South1, Olga Igoucheva5.   

Abstract

Hereditary epidermolysis bullosa (EB) is associated with skin blistering and the development of chronic nonhealing wounds. Although clinical studies have shown that cell-based therapies improve wound healing, the recruitment of therapeutic cells to blistering skin and to more advanced skin lesions remains a challenge. Here, we analyzed cytokines and chemokines in blister fluids of patients affected by dystrophic, junctional, and simplex EB. Our analysis revealed high levels of CXCR1, CXCR2, CCR2, and CCR4 ligands, particularly dominant in dystrophic and junctional EB. In vitro migration assays demonstrated the preferential recruitment of CCR4+ lymphocytes and CXCR1+, CXCR2+, and CCR2+ myeloid cells toward EB-derived blister fluids. Immunophenotyping of skin-infiltrating leukocytes confirmed substantial infiltration of EB-affected skin with resting (CD45RA+) and activated (CD45RO+) T cells and CXCR2+ CD11b+ cells, many of which were identified as CD16b+ neutrophils. Our studies also showed that abundance of CXCR2 ligand in blister fluids also creates a favorable milieu for the recruitment of the CXCR2+ stem cells, as validated by in vitro and in-matrix migration assays. Collectively, this study identified several chemotactic pathways that control the recruitment of leukocytes to the EB-associated skin lesions. These chemotactic axes could be explored for the refinement of the cutaneous homing of the therapeutic stem cells.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28736230      PMCID: PMC5651203          DOI: 10.1016/j.jid.2017.07.002

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  51 in total

Review 1.  Cytokines and wound healing: the role of cytokine and anticytokine therapy in the repair response.

Authors:  Philip A Efron; Lyle L Moldawer
Journal:  J Burn Care Rehabil       Date:  2004 Mar-Apr

2.  Involvement of the CXCL12/CXCR4 pathway in the recovery of skin following burns.

Authors:  Shani Avniel; Zaretski Arik; Alex Maly; Assa Sagie; Hanna Ben Basst; Merav Darash Yahana; Ido D Weiss; Boaz Pal; Ori Wald; Dean Ad-El; Nobutaka Fujii; Fernando Arenzana-Seisdedos; Steffen Jung; Eithan Galun; Eyal Gur; Amnon Peled
Journal:  J Invest Dermatol       Date:  2006-02       Impact factor: 8.551

Review 3.  Physiology of the chronic wound.

Authors:  B C Nwomeh; D R Yager; I K Cohen
Journal:  Clin Plast Surg       Date:  1998-07       Impact factor: 2.017

4.  HB-EGF induces COL7A1 expression in keratinocytes and fibroblasts: possible mechanism underlying allogeneic fibroblast therapy in recessive dystrophic epidermolysis Bullosa.

Authors:  Nikoletta Nagy; Noor Almaani; Akio Tanaka; Joey E Lai-Cheong; Tanasit Techanukul; Jemima E Mellerio; John A McGrath
Journal:  J Invest Dermatol       Date:  2011-04-07       Impact factor: 8.551

5.  Altered balance of epidermis-related chemokines in epidermolysis bullosa.

Authors:  Inkin Ujiie; Yasuyuki Fujita; Chihiro Nakayama; Wakana Matsumura; Shotaro Suzuki; Satoru Shinkuma; Toshifumi Nomura; Riichiro Abe; Hiroshi Shimizu
Journal:  J Dermatol Sci       Date:  2017-01-05       Impact factor: 4.563

6.  Bone marrow transplantation for recessive dystrophic epidermolysis bullosa.

Authors:  John E Wagner; Akemi Ishida-Yamamoto; John A McGrath; Maria Hordinsky; Douglas R Keene; David T Woodley; Mei Chen; Megan J Riddle; Mark J Osborn; Troy Lund; Michelle Dolan; Bruce R Blazar; Jakub Tolar
Journal:  N Engl J Med       Date:  2010-08-12       Impact factor: 91.245

7.  Accelerated wound closure in neutrophil-depleted mice.

Authors:  Julia V Dovi; Li-Ke He; Luisa A DiPietro
Journal:  J Leukoc Biol       Date:  2003-04       Impact factor: 4.962

Review 8.  Granulocyte chemotactic protein-2 and related CXC chemokines: from gene regulation to receptor usage.

Authors:  J Van Damme; A Wuyts; G Froyen; E Van Coillie; S Struyf; A Billiau; P Proost; J M Wang; G Opdenakker
Journal:  J Leukoc Biol       Date:  1997-11       Impact factor: 4.962

9.  Chemotaxis-driven disease-site targeting of therapeutic adult stem cells in dystrophic epidermolysis bullosa.

Authors:  Vitali Alexeev; Adele Donahue; Jouni Uitto; Olga Igoucheva
Journal:  Stem Cell Res Ther       Date:  2016-08-27       Impact factor: 6.832

10.  Proinflammatory Cytokines and Antiskin Autoantibodies in Patients With Inherited Epidermolysis Bullosa.

Authors:  Giuseppina Annicchiarico; Maria Grazia Morgese; Susanna Esposito; Giuseppe Lopalco; Michele Lattarulo; Marilina Tampoia; Domenico Bonamonte; Luigia Brunetti; Antonio Vitale; Giovanni Lapadula; Luca Cantarini; Florenzo Iannone
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

View more
  10 in total

1.  High-Fat Diet Accelerates Carcinogenesis in a Mouse Model of Barrett's Esophagus via Interleukin 8 and Alterations to the Gut Microbiome.

Authors:  Natasha Stephens Münch; Hsin-Yu Fang; Jonas Ingermann; H Carlo Maurer; Akanksha Anand; Victoria Kellner; Vincenz Sahm; Maria Wiethaler; Theresa Baumeister; Frederik Wein; Henrik Einwächter; Florian Bolze; Martin Klingenspor; Dirk Haller; Maria Kavanagh; Joanne Lysaght; Richard Friedman; Andrew J Dannenberg; Michael Pollak; Peter R Holt; Sureshkumar Muthupalani; James G Fox; Mark T Whary; Yoomi Lee; Tony Y Ren; Rachael Elliot; Rebecca Fitzgerald; Katja Steiger; Roland M Schmid; Timothy C Wang; Michael Quante
Journal:  Gastroenterology       Date:  2019-04-15       Impact factor: 22.682

Review 2.  Leading edge: emerging drug, cell, and gene therapies for junctional epidermolysis bullosa.

Authors:  Allison R Keith; Kirk Twaroski; Christen L Ebens; Jakub Tolar
Journal:  Expert Opin Biol Ther       Date:  2020-03-20       Impact factor: 4.388

3.  Beneficial Effect of Systemic Allogeneic Adipose Derived Mesenchymal Cells on the Clinical, Inflammatory and Immunologic Status of a Patient With Recessive Dystrophic Epidermolysis Bullosa: A Case Report.

Authors:  Rocío Maseda; Lucía Martínez-Santamaría; Rosa Sacedón; Nora Butta; María Del Carmen de Arriba; Sara García-Barcenilla; Marta García; Nuria Illera; Isabel Pérez-Conde; Marta Carretero; Eva Jiménez; Gustavo Melen; Alberto M Borobia; Víctor Jiménez-Yuste; Ángeles Vicente; Marcela Del Río; Raúl de Lucas; María José Escámez
Journal:  Front Med (Lausanne)       Date:  2020-11-26

4.  Signatures of Dermal Fibroblasts from RDEB Pediatric Patients.

Authors:  Arkadii K Beilin; Nadezhda A Evtushenko; Daniil K Lukyanov; Nikolay N Murashkin; Eduard T Ambarchian; Alexander A Pushkov; Kirill V Savostyanov; Andrey P Fisenko; Olga S Rogovaya; Andrey V Vasiliev; Ekaterina A Vorotelyak; Nadya G Gurskaya
Journal:  Int J Mol Sci       Date:  2021-02-11       Impact factor: 5.923

Review 5.  Keratins as an Inflammation Trigger Point in Epidermolysis Bullosa Simplex.

Authors:  Nadezhda A Evtushenko; Arkadii K Beilin; Anastasiya V Kosykh; Ekaterina A Vorotelyak; Nadya G Gurskaya
Journal:  Int J Mol Sci       Date:  2021-11-18       Impact factor: 5.923

6.  Clinical trial of ABCB5+ mesenchymal stem cells for recessive dystrophic epidermolysis bullosa.

Authors:  Dimitra Kiritsi; Kathrin Dieter; Elke Niebergall-Roth; Silvia Fluhr; Cristina Daniele; Jasmina Esterlechner; Samar Sadeghi; Seda Ballikaya; Leoni Erdinger; Franziska Schauer; Stella Gewert; Martin Laimer; Johann W Bauer; Alain Hovnanian; Giovanna Zambruno; May El Hachem; Emmanuelle Bourrat; Maria Papanikolaou; Gabriela Petrof; Sophie Kitzmüller; Christen L Ebens; Markus H Frank; Natasha Y Frank; Christoph Ganss; Anna E Martinez; John A McGrath; Jakub Tolar; Mark A Kluth
Journal:  JCI Insight       Date:  2021-11-22

7.  T-cell activation and bacterial infection in skin wounds of recessive dystrophic epidermolysis bullosa patients.

Authors:  Vitali Alexeev; Leonie Huitema; Taylor Phillips; Rodrigo Cepeda; Diego de Los Cobos; Regina Isabella Matus Perez; Mauricio Salas-Garza; Oscar R Fajardo-Ramirez; Franziska Ringpfeil; Jouni Uitto; Julio Cesar Salas-Alanis; Olga Igoucheva
Journal:  Exp Dermatol       Date:  2022-06-06       Impact factor: 4.511

Review 8.  Immunological mechanisms underlying progression of chronic wounds in recessive dystrophic epidermolysis bullosa.

Authors:  Leonie Huitema; Taylor Phillips; Vitali Alexeev; Olga Igoucheva
Journal:  Exp Dermatol       Date:  2021-06-27       Impact factor: 4.511

Review 9.  Overview of the molecular determinants contributing to the expression of Psoriasis and Psoriatic Arthritis phenotypes.

Authors:  Valerio Caputo; Claudia Strafella; Andrea Termine; Annunziata Dattola; Sara Mazzilli; Caterina Lanna; Terenzio Cosio; Elena Campione; Giuseppe Novelli; Emiliano Giardina; Raffaella Cascella
Journal:  J Cell Mol Med       Date:  2020-10-31       Impact factor: 5.295

10.  Translational perspectives to treat Epidermolysis bullosa-Where do we stand?

Authors:  Christine Prodinger; Johann W Bauer; Martin Laimer
Journal:  Exp Dermatol       Date:  2020-11       Impact factor: 4.511

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.